413 related articles for article (PubMed ID: 29149761)
1. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
2. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.
Schöffski P; Wozniak A; Stacchiotti S; Rutkowski P; Blay JY; Lindner LH; Strauss SJ; Anthoney A; Duffaud F; Richter S; Grünwald V; Leahy MG; Reichardt P; Sufliarsky J; van der Graaf WT; Sciot R; Debiec-Rychter M; van Cann T; Marréaud S; Lia M; Raveloarivahy T; Collette L; Bauer S
Ann Oncol; 2017 Dec; 28(12):3000-3008. PubMed ID: 28950372
[TBL] [Abstract][Full Text] [Related]
3. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.
Schöffski P; Wozniak A; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Gelderblom H; Italiano A; Lindner LH; Hennig I; Strauss S; Zakotnik B; Anthoney A; Albiges L; Blay JY; Reichardt P; Sufliarsky J; van der Graaf WTA; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Raveloarivahy T; Collette S; Stacchiotti S
Ann Oncol; 2018 Mar; 29(3):758-765. PubMed ID: 29216400
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
5. The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
Schöffski P; Wozniak A; Leahy MG; Aamdal S; Rutkowski P; Bauer S; Richter S; Grünwald V; Debiec-Rychter M; Sciot R; Geoerger B; Marréaud S; Collette S; Nzokirantevye A; Strauss SJ
Eur J Cancer; 2018 May; 94():156-167. PubMed ID: 29567632
[TBL] [Abstract][Full Text] [Related]
6. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S
Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019
[No Abstract] [Full Text] [Related]
7. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
8. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Choueiri TK; Plimack E; Arkenau HT; Jonasch E; Heng DYC; Powles T; Frigault MM; Clark EA; Handzel AA; Gardner H; Morgan S; Albiges L; Pal SK
J Clin Oncol; 2017 Sep; 35(26):2993-3001. PubMed ID: 28644771
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski P; Sufliarsky J; Gelderblom H; Blay JY; Strauss SJ; Stacchiotti S; Rutkowski P; Lindner LH; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Van Cann T; Marréaud S; Nzokirantevye A; Collette S; Wozniak A
Lancet Respir Med; 2018 Jun; 6(6):431-441. PubMed ID: 29669701
[TBL] [Abstract][Full Text] [Related]
11. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
[TBL] [Abstract][Full Text] [Related]
13. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
Angevin E; Spitaleri G; Rodon J; Dotti K; Isambert N; Salvagni S; Moreno V; Assadourian S; Gomez C; Harnois M; Hollebecque A; Azaro A; Hervieu A; Rihawi K; De Marinis F
Eur J Cancer; 2017 Dec; 87():131-139. PubMed ID: 29145039
[TBL] [Abstract][Full Text] [Related]
14. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri TK; Vaishampayan U; Rosenberg JE; Logan TF; Harzstark AL; Bukowski RM; Rini BI; Srinivas S; Stein MN; Adams LM; Ottesen LH; Laubscher KH; Sherman L; McDermott DF; Haas NB; Flaherty KT; Ross R; Eisenberg P; Meltzer PS; Merino MJ; Bottaro DP; Linehan WM; Srinivasan R
J Clin Oncol; 2013 Jan; 31(2):181-6. PubMed ID: 23213094
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
Choueiri TK; Heng DYC; Lee JL; Cancel M; Verheijen RB; Mellemgaard A; Ottesen LH; Frigault MM; L'Hernault A; Szijgyarto Z; Signoretti S; Albiges L
JAMA Oncol; 2020 Aug; 6(8):1247-1255. PubMed ID: 32469384
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
17. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
Escudier B; Molinie V; Bracarda S; Maroto P; Szczylik C; Nathan P; Negrier S; Weiss C; Porta C; Grünwald V; Albiges L
Eur J Cancer; 2016 Dec; 69():226-235. PubMed ID: 27680407
[TBL] [Abstract][Full Text] [Related]
18. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.
Rochigneux P; Thomassin-Piana J; Laibe S; Brunelle S; Salem N; Escudier B; Vassal G; Gravis G
BMC Cancer; 2018 Nov; 18(1):1159. PubMed ID: 30466410
[TBL] [Abstract][Full Text] [Related]
20. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Pal SK; Tangen C; Thompson IM; Balzer-Haas N; George DJ; Heng DYC; Shuch B; Stein M; Tretiakova M; Humphrey P; Adeniran A; Narayan V; Bjarnason GA; Vaishampayan U; Alva A; Zhang T; Cole S; Plets M; Wright J; Lara PN
Lancet; 2021 Feb; 397(10275):695-703. PubMed ID: 33592176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]